Genmab A/S (NASDAQ:GMAB) Receives “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a research report sent to investors on Wednesday morning, Benzinga reports. The brokerage currently has a $50.00 target price on the stock.

Several other equities research analysts also recently commented on the company. Truist Financial dropped their target price on Genmab A/S from $53.00 to $50.00 and set a “buy” rating on the stock in a report on Monday, September 9th. Royal Bank of Canada upgraded shares of Genmab A/S from a “sector perform” rating to an “outperform” rating in a research note on Monday, July 15th. Redburn Atlantic started coverage on shares of Genmab A/S in a research note on Tuesday, October 8th. They issued a “buy” rating for the company. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Genmab A/S in a research note on Tuesday, August 20th. Finally, BTIG Research boosted their price objective on shares of Genmab A/S from $46.00 to $47.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Genmab A/S has an average rating of “Moderate Buy” and an average price target of $45.20.

Genmab A/S Stock Down 2.5 %

GMAB opened at $22.60 on Wednesday. Genmab A/S has a 52-week low of $22.52 and a 52-week high of $33.45. The company has a 50 day moving average of $25.89 and a two-hundred day moving average of $27.18. The company has a market cap of $14.95 billion, a P/E ratio of 18.83, a P/E/G ratio of 0.71 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Thursday, August 8th. The company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.07). Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. The business had revenue of $779.50 million for the quarter, compared to analysts’ expectations of $734.60 million. Research analysts anticipate that Genmab A/S will post 1.27 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Benjamin F. Edwards & Company Inc. raised its position in shares of Genmab A/S by 7.1% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock worth $182,000 after purchasing an additional 478 shares during the period. Russell Investments Group Ltd. increased its position in Genmab A/S by 137.7% in the first quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock worth $28,000 after buying an additional 544 shares during the period. Envestnet Portfolio Solutions Inc. increased its position in Genmab A/S by 2.3% in the first quarter. Envestnet Portfolio Solutions Inc. now owns 27,755 shares of the company’s stock worth $830,000 after buying an additional 633 shares during the period. GAMMA Investing LLC lifted its stake in Genmab A/S by 194.0% in the first quarter. GAMMA Investing LLC now owns 1,135 shares of the company’s stock valued at $34,000 after buying an additional 749 shares during the last quarter. Finally, Grandfield & Dodd LLC boosted its holdings in shares of Genmab A/S by 3.4% during the first quarter. Grandfield & Dodd LLC now owns 26,418 shares of the company’s stock valued at $790,000 after acquiring an additional 860 shares during the period. 7.07% of the stock is currently owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.